Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07001748 · ClinicalTrials.gov registry record · Phase 2
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
A Phase 2 study of Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by ECOG-ACRIN Cancer Research Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 10
- Study locations
NCT07001748 is a Phase 2 study of Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma that is actively recruiting participants, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 148 participants, below the 242-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (39% lower). The trial reports 10 study locations across 5 states.
The verdict
NCT07001748, a Phase 2 study of Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, is actively recruiting participants, sponsored by ECOG-ACRIN Cancer Research Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdominal cavity in addition to chemotherapy given through a vein in your arm? Will administering paclitaxel chemotherapy directly into your abdominal cavity, in addition to chemotherapy given through a vein in your arm help you live longer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your gastric cancer. The usual approach is defined as care most people get for gastric cancer. If you decide to take part in this study, you will first receive a surgical procedure called a diagnostic laparoscopy. This will help the study doctors learn more about your gastric cancer. Laparoscopy is a minimally invasive surgery for which you will be placed under general anesthesia. Then the surgeon will make small incisions (5mm) on your belly through which a camera and thin instruments are introduced to evaluate the abdomen. This procedure takes about 1 hour to complete. Your study group will be assigned during the surgery. The study groups are described further in the 'What are the study groups?' section below. If you are placed into the study group 1, you will not have an intraperitoneal port (a small device which is placed under the skin and fat of your upper abdomen and a tube that is placed into the abdomen). If you are placed into the study group 2, you will have an intraperitoneal port placed. The reason is that in addition to standard chemotherapy, which is given through a vein in your arm, this port will be used to deliver the medication paclitaxel directly inside your abdomen when you are ready to start study treatment. It is important to know that you will not know your study group until after the surgery is over. This is because information that is learned during the surgery will help determine which study gr
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Diagnostic Laparoscopy
- DRUG Standard of Care Chemotherapy
- PROCEDURE Intraperitoneal Port Placement
Study Locations (10)
Florida
- Schulze Family Foundation Cancer Clinic - Bonita Health Center - Bonita Springs
- Lee Memorial Health System - Fort Myers
- Regional Cancer Center-Lee Memorial Health System - Fort Myers
California
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Irvine
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Orange
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
- UPMC-Passavant Hospital - Pittsburgh
Wisconsin
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center - Madison
- University of Wisconsin Carbone Cancer Center - University Hospital - Madison
Kentucky
- University of Kentucky/Markey Cancer Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2025-08-19 |
| Est. Completion | 2030-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07001748
The ClinicalTrials.gov registry entry for NCT07001748 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (39% lower). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07001748 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07001748 about?
NCT07001748 is a clinical study titled "Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity". This study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdominal cavity in addition to chemotherapy given through a vein in your arm? Will administering paclitax...
What is the current status of trial NCT07001748?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2025-08-19. Estimated completion is 2030-05-30.
What conditions does trial NCT07001748 study?
This clinical trial studies the following conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis.
What interventions are being tested in trial NCT07001748?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Diagnostic Laparoscopy (PROCEDURE), Standard of Care Chemotherapy (DRUG), Intraperitoneal Port Placement (PROCEDURE).
Who is sponsoring clinical trial NCT07001748?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07001748 being conducted?
This trial has 10 study locations across California, Florida, Kentucky, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
RECRUITING · Phase 2
-
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
RECRUITING · Phase 2
-
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
-
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
RECRUITING · Phase 2
Explore more on PlainTrial
Gastric Adenocarcinoma
All registered trials for this condition
Gastroesophageal Junction Adenocarcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.